Transcatheter aortic valve replacement as effective as surgery in intermediate patients

Medtronic plc (NYSE: MDT) today unveiled first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial.